Impact of nutritional status on the pharmacokinetics of erlotinib in rats.

about

Impact of Undernutrition on the Pharmacokinetics and Pharmacodynamics of Anticancer Drugs: A Literature Review.Levofloxacin effect on erlotinib absorption. Evaluation of the interaction in undernutrition situations through population pharmacokinetic analysis in rats.

P2860

Q38869469-8FAF90A8-ECF1-4DE1-AE73-F093D502F5C7 Q50947265-7B962159-B069-4FCC-90F9-70FC6AAE4AE0

P2860

Impact of nutritional status on the pharmacokinetics of erlotinib in rats.

Item

http://www.wikidata.org/entity/Q54284937

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Impact of nutritional status on the pharmacokinetics of erlotinib in rats.

@en

Impact of nutritional status on the pharmacokinetics of erlotinib in rats.

@nl

type

Item

label

Impact of nutritional status on the pharmacokinetics of erlotinib in rats.

@en

Impact of nutritional status on the pharmacokinetics of erlotinib in rats.

@nl

prefLabel

Impact of nutritional status on the pharmacokinetics of erlotinib in rats.

@en

Impact of nutritional status on the pharmacokinetics of erlotinib in rats.

@nl

P1476

Impact of nutritional status on the pharmacokinetics of erlotinib in rats

@en

P2093

A Pérez-Pitarch

http://www.w3.org/2001/XMLSchema#string

N V Jiménez-Torres

http://www.w3.org/2001/XMLSchema#string

P2860

The effect of dietary protein depletion on hepatic 5-fluorouracil metabolism

Cancer anorexia and cachexia.

Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation.

Interactions of tyrosine kinase inhibitors with organic cation transporters and multidrug and toxic compound extrusion proteins

The stomach in malnutrition.

Intestinal permeability in kwashiorkor.

Role of nutritional status in predicting quality of life outcomes in cancer--a systematic review of the epidemiological literature.

Should the concomitant use of erlotinib and acid-reducing agents be avoided? The drug interaction between erlotinib and acid-reducing agents.

Clinical pharmacokinetics of tyrosine kinase inhibitors: focus on 4-anilinoquinazolines.

Intestinal biopsy in kwashiorkor.

P304

373-384

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/BDD.1948

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Matilde Merino-Sanjuán

Virginia Merino

Amparo Nácher

A Catalán-Latorre

P577

2015-04-16T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

273464801

http://www.w3.org/2001/XMLSchema#string

P698

25765899

http://www.w3.org/2001/XMLSchema#string

Impact of nutritional status on the pharmacokinetics of erlotinib in rats.

about

P2860

P2860

Impact of nutritional status on the pharmacokinetics of erlotinib in rats.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P5875

P698